Literature DB >> 17653803

Post operative infection and increased survival in osteosarcoma patients: are they associated?

L M Jeys1, R J Grimer, S R Carter, R M Tillman, A Abudu.   

Abstract

BACKGROUND: Despite neo-adjuvant chemotherapy osteosarcomas having significant mortality, recent studies have shown survival advantages following infections for some tumour types. This study investigates the effect of post-operative infection in patients treated for osteosarcoma using endoprosthetic replacement and neo-adjuvant chemotherapy.
MATERIAL AND METHODS: A consecutive series of 547 patients underwent surgery between 1981 and 2001 for osteosarcoma. Patients were excluded from the study if over 60 years old at diagnosis (n = 14) as they would not routinely receive chemotherapy. Studies showed that 70% of deep infections occur within one year from reconstruction. Therefore landmark analysis was performed; all patients infected after 12 months of reconstruction were excluded (15 patients, 2.7%) and those who died within 12 months from diagnosis due to metastases were excluded (105 patients, 19.2%), leaving 412 patients. Any survival advantage of early infection was analysed by Kaplan-Meier survival analysis from this landmark point.
RESULTS: Overall population survival was 65% at 10 years after landmarking. There were 41 patients (10%) who developed an infection within one year of implantation. These patients had significantly better survival (p = 0.017). The 10-year survival for patients with osteosarcoma with infection was 84.5% compared to 62.3% in the non-infected group after landmarking. There was no significant difference in the percentage post-chemotherapy specimen necrosis between the two groups (p = 0.36). Infection was an independent prognostic factor on cox regression analysis.
CONCLUSIONS: There was evidence for increased survival after deep post-operative infection in osteosarcoma patients, in keeping with other research. The authors feel this warrants further investigation.

Entities:  

Mesh:

Year:  2007        PMID: 17653803     DOI: 10.1245/s10434-007-9483-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  49 in total

Review 1.  Management of infection following reconstruction in bone tumors.

Authors:  Sudhir K Kapoor; Rajesh Thiyam
Journal:  J Clin Orthop Trauma       Date:  2015-07-07

2.  Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.

Authors:  P M Anderson; P Meyers; E Kleinerman; K Venkatakrishnan; D P Hughes; C Herzog; W Huh; R Sutphin; Y M Vyas; V Shen; A Warwick; N Yeager; C Oliva; B Wang; Y Liu; A Chou
Journal:  Pediatr Blood Cancer       Date:  2013-08-31       Impact factor: 3.167

Review 3.  Bone microenvironment signals in osteosarcoma development.

Authors:  Arantzazu Alfranca; Lucia Martinez-Cruzado; Juan Tornin; Ander Abarrategi; Teresa Amaral; Enrique de Alava; Pablo Menendez; Javier Garcia-Castro; Rene Rodriguez
Journal:  Cell Mol Life Sci       Date:  2015-05-03       Impact factor: 9.261

4.  Immune dysregulation and osteosarcoma: Staphylococcus aureus downregulates TGF-β and heightens the inflammatory signature in human and canine macrophages suppressed by osteosarcoma.

Authors:  Joanne L Tuohy; Jason A Somarelli; Luke B Borst; William C Eward; B Duncan X Lascelles; Jonathan E Fogle
Journal:  Vet Comp Oncol       Date:  2019-10-15       Impact factor: 2.613

5.  CORR Insights®: Intratibial Injection Causes Direct Pulmonary Seeding of Osteosarcoma Cells and Is Not a Spontaneous Model Metastasis: A Mouse Osteosarcoma Model.

Authors:  Daniel M Lerman
Journal:  Clin Orthop Relat Res       Date:  2018-07       Impact factor: 4.176

6.  [Tumor prostheses : Important in modern revision arthroplasty].

Authors:  A Hillmann; I Ipach
Journal:  Orthopade       Date:  2015-05       Impact factor: 1.087

7.  CORR Insights™: High infection rate outcomes in long-bone tumor surgery with endoprosthetic reconstruction in adults: a systematic review.

Authors:  John H Healey
Journal:  Clin Orthop Relat Res       Date:  2013-03-12       Impact factor: 4.176

Review 8.  Advancing therapy for osteosarcoma.

Authors:  Jonathan Gill; Richard Gorlick
Journal:  Nat Rev Clin Oncol       Date:  2021-06-15       Impact factor: 66.675

9.  Review of mifamurtide in the treatment of patients with osteosarcoma.

Authors:  Leo Kager; Ulrike Pötschger; Stefan Bielack
Journal:  Ther Clin Risk Manag       Date:  2010-06-24       Impact factor: 2.423

Review 10.  Canine sarcomas as a surrogate for the human disease.

Authors:  Daniel L Gustafson; Dawn L Duval; Daniel P Regan; Douglas H Thamm
Journal:  Pharmacol Ther       Date:  2018-03-09       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.